Condition 1: Menopause Symptomes. Condition 2: menopause. Menopausal and female climacteric states States associated with artificial menopause
Conditions
Interventions
Intervention 1: Intervention 1:
Oral use of 530 mg Valerian capsules, twice a day, for two months. Intervention 2: Intervention 2:
Oral use of 250 mg Lemon Balm capsules, twice a day, for two months
Prevention
Placebo
Intervention 1:
Oral use of 530 mg Valerian capsules, twice a day, for two months
Intervention 2:
Oral use of 250 mg Lemon Balm capsules, twice a day, for two months
Intervention 3:
Oral use of 80 mg Lemon Balm and 160 mg Valerian combined capsule, twice a day, for two months
Placebo Group: Oral use of 300 mg starch capsules, twice a day, for two months
Sponsors
Faculty of Nursing and Midwifery, Tehran University of Medical Sciences
Vice Chancellor for Research, Iran University of Medical Sciences (Reserach proposal)
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: cessation of menstruation at least for 12 months due to menopause; no history of allergy to valerian, lemon balm and both of them; no history of drug use in the past two months, such as hormone replacement therapy and psychotic drugs etc. Exclusion Criteria: any kind of side effects during treatment such as allergy to valerian, lemon balm and both of them; no taking of oral capsules valerian, lemon balm and both of them for a maximum period of seven days or more during any month of consumption; using any kind of drug throughout the study; occurrence of any individual or family crisis during research process; any kind of change in diet and life style such as changing to vegetarianism diet during the research process; any health problems or addictions throughout research process.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hot flush. Timepoint: Before intervention, at the end of first and second month after intervention. Method of measurement: Menopause Rating Scale Questionnaire.;Depression. Timepoint: Before intervention, at the end of first and second month after intervention. Method of measurement: Menopause Rating Scale Questionnaire.;Tachycardia. Timepoint: Before intervention, at the end of first and second month after intervention. Method of measurement: Menopause Rating Scale Questionnaire.;Insomnia. Timepoint: Before intervention, at the end of first and second month after intervention. Method of measurement: Menopause Rating Scale Questionnaire.;Anxiety. Timepoint: Before intervention, at the end of first and second month after intervention. Method of measurement: Menopause Rating Scale Questionnaire.;Vaginal dryness. Timepoint: Before intervention, at the end of first and second month after intervention. Method of measurement: Menopause Rating Scale Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSimin Taavoni
Nursing and Midwifery Faculty of Iran University of Medical Sciences
Outcome results
None listed